Navigation Links
Evotec AG: R&D Update on 16 October 2007 Live on the Internet
Date:10/9/2007

HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.

Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.

To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Merge announces sofware updates, upcoming acquisition
3. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
4. Solinus updates MailFoundry anti-spam hardware, switching to Linux
5. Dane County mapping software updated, available to public
6. Wingra Technologies updates data migration software
7. Firstlogics mailing-address update system gains Postal Service certification
8. Lands End Debuts Updated Virtual Model
9. Internet-enabled niche markets take center stage
10. Emergence of Internet video is changing the regulatory landscape
11. Viewing the Internet as a free-for-all can be costly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/19/2017)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ... a live webcast of its Annual Meeting of Shareholders on Tuesday, ... webcast can be accessed from the BD corporate website at ... 2017. ... BD BD is a global medical technology company that is ...
(Date:1/18/2017)... 2017 According to a new market research report "In ... Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global ... 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/22/2016)... , December 22, 2016 SuperCom (NASDAQ: ... secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors ... SuperCom, has been selected to implement and deploy a community-based supportive ... Northern California , further expanding its presence in the ... This new ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):